SIRION Biotech - Europe's leading Commercial Vector Core
August 7, 2015: Progress Published in Screening for New Cancer Compounds in Context of Radiation Therapy
SIRION has shifted the paradigm among viral vector partners by providing all three major vector types, adenovirus (AV),adeno-associated virus (AAV) and lentivirus (LV), covered by intellectual property (IP) claims which are pending worldwide. With world leading expertise in the field of transduction and innovative solutions that account for quantity and purity issues, SIRION delivers on-time, on-budget and is setting new standards in quality and performance.
• Adenovirus (AV): Based on proprietary BAC technology which allows for construction of rare adenovirus serotypes for vaccine development, our AV preparations are available on a fee-for-service basis and made in 4-6 weeks. Clinical use of AV serotypes is possible with licensing agreements.
• Adeno-associated virus (AAV): Our AAV purities and concentrations are superior as supported by our high standard quality controls and confirmed in a recent independent publication. Of specific interest are tissue specific AAV and capsid mutations. Clinical use is possible with licensing agreements.
Lentivirus: Our proprietary, Lenti-BOOST™ and Lenti-THERAPY™ provide superior and
specific transduction efficiencies.
Lenti-BOOST is based on a non-toxic chemical which
increases the permeability of cell membranes,
allowing lentiviruses easy access. Clinical use is
possible with licensing agreements